Company Description
Merck & Co., Inc. operates as a healthcare company worldwide.
It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
vIt has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications.
It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.
The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
| Country | United States |
| Founded | 2000 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 72,000 |
| CEO | Robert Davis |
Contact Details
Address: 126 East Lincoln Avenue Rahway, New Jersey 07065 United States | |
| Phone | 908 740 4000 |
| Website | merck.com |
Stock Details
| Ticker Symbol | MRK |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000310158 |
| CUSIP Number | 58933Y105 |
| ISIN Number | US58933Y1055 |
| Employer ID | 22-1918501 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert M. Davis J.D. | Chairman, President and Chief Executive Officer |
| Caroline Litchfield | Executive Vice President and Chief Financial Officer |
| Richard R. DeLuca Jr. | Executive Vice President and President of Merck Animal Health |
| Sanat Chattopadhyay | Executive Vice President and President of Merck Manufacturing Division |
| Dr. Dean Y. Li M.D., Ph.D. | Executive Vice President and President of Merck Research Laboratories |
| Dalton E. Smart III | Senior Vice President of Finance, Principal Accounting Officer and Global Controller |
| David Michael Williams | Executive Vice President and Chief Information and Digital Officer |
| Peter Dannenbaum | Vice President of Investor Relations |
| Cristal N. Downing | Executive Vice President and Chief Communications and Public Affairs Officer |
| Betty D. Larson | Executive Vice President and Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 22, 2024 | 8-K | Current Report |
| Nov 6, 2024 | 10-Q | Quarterly Report |
| Nov 4, 2024 | 25-NSE | Filing |
| Oct 31, 2024 | 8-K | Current Report |
| Aug 5, 2024 | 10-Q | Quarterly Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jun 25, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 25, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| Jun 25, 2024 | 11-K | Annual report of employee stock purchase, savings and similar plans |
| May 30, 2024 | CERT | Certification by an exchange approving securities for listing |